## Overcoming multidrug resistance by a combination of chemotherapy and

## photothermal therapy mediated by carbon nanohorns

Junling Wang,<sup>a</sup> Ran Wang,<sup>a</sup> Fangrong Zhang,<sup>b</sup> Yajun Yin,<sup>a</sup> Leixia Mei,<sup>a</sup> Fengjuan Song,<sup>a</sup> Mingtao Tao<sup>a</sup>, Wanqing Yue,<sup>a</sup> Wenying Zhong<sup>a, c, †</sup>

<sup>a</sup> Department of analytical chemistry, China Pharmaceutical University, Nanjing 210009, PR China

<sup>b</sup> State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China

<sup>c</sup> Key Laboratory of Biomedical Functional Materials, China Pharmaceutical University, Nanjing 210009, PR China

<sup>&</sup>lt;sup>†</sup> Corresponding author. Tel.: +86-025-86185180; fax: +86-025-86185160

E-mail address: wyzhong@cpu.edu.cn. (W. Zhong).





Fig. S1. The structure of etoposide (ETO)



Fig. S2 The histogram of A549 and A549R cells incubated with ETO@oxCNHs/PEG-PA-FITC at 37

°C for 4 h.



Fig. S3 The histogram of A549R cells incubated with ETO@oxCNHs/PEG-PA-FITC at 4 °C or 37 °C.



Fig. S4 Histologic assessments of major organs and tumor tissues with H-E staining in mice (200×). (A) NS; (B) oxCNHs/PEG-PA; (C) ETO; (D) ETO@oxCNHs/PEG; (E) ETO@oxCNHs/PEG-PA; (F) ETO@oxCNHs/PEG-PA + NIR.